Cue Biopharma (NASDAQ:CUE) posted its quarterly earnings results on Tuesday. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.15), MarketWatch Earnings reports. Cue Biopharma had a negative return on equity of 103.99% and a negative net margin of 959.08%.
Shares of NASDAQ CUE opened at $30.54 on Friday. Cue Biopharma has a 1 year low of $6.54 and a 1 year high of $30.99. The stock’s 50-day simple moving average is $21.78 and its 200-day simple moving average is $16.30. The firm has a market cap of $817.80 million, a price-to-earnings ratio of -18.85 and a beta of 2.25.
A number of analysts have recently commented on the company. BTIG Research upped their price objective on Cue Biopharma from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday. Oppenheimer upped their price target on Cue Biopharma from $27.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday. Zacks Investment Research lowered Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. JMP Securities upped their price target on Cue Biopharma from $22.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, March 6th. Finally, BidaskClub raised Cue Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $28.00.
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Read More: Inverted Yield Curve
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.